WO2019221488A1 - Formulation pharmaceutique comprenant de l'apixaban et son procédé de préparation - Google Patents

Formulation pharmaceutique comprenant de l'apixaban et son procédé de préparation Download PDF

Info

Publication number
WO2019221488A1
WO2019221488A1 PCT/KR2019/005795 KR2019005795W WO2019221488A1 WO 2019221488 A1 WO2019221488 A1 WO 2019221488A1 KR 2019005795 W KR2019005795 W KR 2019005795W WO 2019221488 A1 WO2019221488 A1 WO 2019221488A1
Authority
WO
WIPO (PCT)
Prior art keywords
apixaban
weight
pharmaceutical formulation
lag time
release
Prior art date
Application number
PCT/KR2019/005795
Other languages
English (en)
Inventor
Seokyoung KWON
Yunsang Park
Daehwan KOO
Youngbin Lee
Original Assignee
Sinil Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinil Pharmaceutical Co., Ltd. filed Critical Sinil Pharmaceutical Co., Ltd.
Publication of WO2019221488A1 publication Critical patent/WO2019221488A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a pharmaceutical formulation comprising an apixaban and a method for preparing the same.
  • Apixaban is a known compound represented by the following chemical formula 1:
  • apixaban is 4,5,6,7-tetrahydro-l-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-l-piperidinyl)phenyl]-lH-pyrazolo[3,4-c]pyridine-3-carboxamide (CAS name) or l-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-l-piperidinyl)phenyl]-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-c]pyridine-3-carboxamide.
  • Apixaban is a factor Xa inhibitor disclosed in U.S. Patent No. 6,967,208, which discloses that it may be administrated in the form of a pharmaceutical formulation containing at least one pharmaceutically acceptable diluent or carrier.
  • Apixaban is a substance that has high water solubility in the drug itself, but is difficult to obtain a constant bioavailability according to the dosage form and is hydrolyzed when exposed to moisture (Sci Pharm. 2014(82)777-785).
  • the apixaban itself is a non-hygroscopic substance, but when it is stored under high temperature and high humidity conditions due to the additives contained for formulation into oral dosage form, the moisture of the tablet is increased and the apixaban is hydrolyzed accordingly.
  • a decrease in content of apixaban by moisture, a decrease in therapeutic effect due to degraded apixaban, and an increase in side effects may occur.
  • Korean Patent Application Laid-Open No. 10-2012-0029428 discloses a bilayer osmotic controlled release dosage form of apixaban. Said application discloses that the dosage form can minimize the number of drug doses and can provide a controlled release dosage form regardless of a meal.
  • Korean Patent Laid-Open No. 10-2014-0046395 discloses a pharmaceutical composition for oral administration, comprising a factor Xa inhibitor and heavy chain fatty acid or an enhancer having a carbon chain length of from 4 to 20 carbon atoms. Said application discloses that a water-in-oil microemulsion composition provides a reproducible and predictable bioavailability.
  • Korean Patent Laid-Open No. 10-2016-0098508 discloses a formulation wherein a factor Xa inhibitor including an apixaban is micronized and a solubilizer is adsorbed on the surface.
  • Korean Patent Laying-Open No. 10-2009-0052346 discloses that a pharmaceutical composition comprising a plurality of small tablets containing an Xa inhibitor including apixaban as a pharmaceutical composition capable of having modified release.
  • Korean Patent No. 10-1796300 also discloses a pharmaceutical formulation comprising a crystalline apixaban particle having a limited maximum size.
  • Said application discloses how to use apixaban particles having a particle size of a certain value or less to provide a pharmaceutical composition that does not impose limitations on solubility and bioavailability.
  • the present invention has been devised to solve the above problems of the prior arts, and
  • an object of the present invention to provide an apixaban pharmaceutical formulation, which is capable of stably dissolving apixaban and providing its excellent bioavailability by its immediate-release property after the initial delayed release, even when short-term fluctuation of pH occurs in the stomach upon oral administration of the drug.
  • an object of the present invention to provide an apixaban pharmaceutical formulation, which is capable of being formulated into a form which is hardly affected by the digestion process of food by its immediate-release property after the initial delayed release even when it is taken with meals or after meals to be very convenient to take and have more excellent therapeutic effect; and which is capable of being formulated into a form which is hardly affected by other drugs even when taken along with other drugs to be very convenient to take and have more excellent therapeutic effect.
  • the present invention provides
  • a pharmaceutical formulation for delayed release of drug comprising: a core comprising at least one selected from the group consisting of an apixaban and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and a coated layer for the core,
  • a lag time is from 5 to 360 minutes and 60% or more by weight of the apixaban dissolve within 60 minutes after the lag time, wherein the lag time is defined as the time at which the dissolution rate of apixaban is detected to be less than 10% by weight, as measured in 900 mL of dissolution medium at 37°C using a USP Apparatus 2 at a rotation speed of 75 rpm.
  • the present invention provides a method for preparing a pharmaceutical formulation of the present invention, comprising the steps of:
  • step (b) compressing the mixture from step (a) by a direct compression method to produce a core tablet, or dry-granulating and compressing the mixture from step (a) to produce a core tablet;
  • An apixaban pharmaceutical formulation provides the effect of stably dissolving apixaban and providing its excellent bioavailability by having its immediate-release function after the initial delayed release by a coated layer, even when short-term fluctuation of pH occurs in the stomach upon administration of the drug.
  • the pharmaceutical formulation of the present invention can be formulated into a form which is hardly affected by the digestion process of food even when it is taken with meals or after meals to provide excellent convenience of taking as well as provide more excellent therapeutic effect; and can be formulated into a form which hardly affected by other drugs even when taken along with other drugs to provide excellent convenience of taking as well as provide more excellent therapeutic effect.
  • the apixaban pharmaceutical formulation of the present invention prevents moisture from penetrating into the formulation by a coated layer to prevent the hydrolysis of apixaban and the production of impurities, thereby providing the excellent storage stability.
  • the method for preparing a pharmaceutical formulation of the present invention provides a method for efficiently preparing an apixaban pharmaceutical formulation having the above effects.
  • Fig. 1 is a graph showing apixaban dissolution profiles of apixaban pharmaceutical formulations of example 2 and comparative example 1.
  • Fig. 2 is a graph showing apixaban dissolution profiles of apixaban pharmaceutical formulations of examples 1 to 5.
  • Fig. 3 is a graph showing the blood apixaban concentration profile in a beagle dog of a commercially available Eliquis Tab. 5 mg and a pharmaceutical preparation of example 2.
  • Fig. 4 is a graph showing a relationship between a lag time of apixaban drug and 60% by weight of a release time after initial delayed release according to the content of Eudragit E as a coating material.
  • Fig. 5 is a graph showing a relationship between a lag time of apixaban drug and 60% by weight of a release time after initial delayed release according to the content of EC;PVA as a coating material.
  • Fig. 6 is a graph showing a relationship between a lag time of apixaban drug and 60% by weight of a release time after initial delayed release according to the content of EC;HPMC as a coating material.
  • the present invention relates to an apixaban pharmaceutical formulation for delayed release of drug, comprising: a core comprising at least one selected from the group consisting of an apixaban and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and a coated layer for the core, characterized in that
  • a release lag time is from 5 to 360 minutes and 60% or more by weight of the apixaban dissolve within 60 minutes after the release lag time, wherein the release lag time is defined as the time at which the dissolution rate of apixaban is detected to be less than 10% by weight, as measured in 900 mL of dissolution medium at 37°C using a USP Apparatus 2 at a rotation speed of 75 rpm.
  • an apixaban pharmaceutical formulation is designed to release the drug from the start after the administration of the formulation without the delayed release of a certain period of time as in the prior arts, a change in the drug release pattern due to short-term fluctuation in gastric pH by food and co-administered drug may occur, and furthermore apixaban may be degraded by food and co-administered drug and decreased absorption due to competitive absorption and increased absorption by lipid materials may occur.
  • the gastric pH is between 1 and 2 on fasting but increases to 3.5 to 5.0 on meals, and this short-term rise in pH has a large effect on the absorption of the drug according to the pH-partition theory (Kor. J. Clin. Pharm 16(2) 2006 147-154).
  • the pharmaceutical formulation of the present invention has an important technical feature that a release lag time is from 5 to 360 minutes and 60% or more by weight of the apixaban is controlled to dissolve within 60 minutes after the release lag time. That is, the pharmaceutical formulation of the present invention has immediate-release property after the initial delayed release.
  • the release lag time is defined as a time at which the dissolution rate of apixaban is detected to be less than 10% by weight or it may be defined as a time from zero to the last time point in minute at which the dissolution rate of apixaban is detected to be less than 10% by weight.
  • the apixaban passes through the stomach and small intestine to be released in the large intestine where the water is relatively small, and thus the drug may not be sufficiently dissolved due to a small amount of water and absorption may not be smooth.
  • the drug release lag time is appropriately from 5 to 360 minutes.
  • the enteric coated layer is collapsed due to short-term fluctuation of gastric pH to be able to result in unwanted drug release, and there is a possibility that the dissolution of the drug is changed due to the pH change to be able to change the drug release rate of the sustained release formulations, and thus the effect of the present invention is not obtained.
  • the drug release lag time is from 5 to 360 minutes and the apixaban may dissolve by 70 % or more within 60 minutes after the release lag time.
  • the drug release lag time is from 10 to 150 minutes and the apixaban may dissolve 77 % or more by weight within 60 minutes after the release lag time.
  • the pharmaceutical formulation of the present invention is characterized in that the release lag time is from 5 to 360 minutes and 60 % or more by weight of the apixaban dissolve within 60 minutes after the release lag time, wherein the release lag time is defined as the time at which the dissolution rate of apixaban is detected to be less than 1 % by weight, as measured in 900 mL of dissolution medium at 37°C using a USP Apparatus 2 at a rotation speed of 75 rpm.
  • the pharmaceutical formulation of the present invention is characterized in that the release lag time is from 30 to 150 minutes and 70 % or more by weight of the apixaban dissolve within 60 minutes after the release lag time, wherein the release lag time is defined as the time at which the dissolution rate of apixaban is detected to be less than 3 % by weight, as measured in 900 mL of dissolution medium at 37°C using a USP Apparatus 2 at a rotation speed of 75 rpm.
  • the apixaban dissolves 70 % or more by weight within 30 minutes after the release lag time.
  • the pharmaceutical formulation of the present invention is characterized in that the lag time is from 30 to 150 minutes and 70 % or more by weight of the apixaban dissolve within 60 minutes after the release lag time, wherein the release lag time is defined as the time at which the dissolution rate of apixaban is detected to be less than 1 % by weight, as measured in 900 mL of dissolution medium at 37°C using a USP Apparatus 2 at a rotation speed of 75 rpm.
  • the apixaban dissolves 70 % or more by weight within 30 minutes after the release lag time.
  • the pharmaceutical formulation having the above-described release lag time of 30 to 150 minutes may be taken in the form which is hardly affected by the digestion process of food even when it is taken with meals or after meals to be very convenient to take and have more improved therapeutic effect accordingly, and thus it may be a very desirable form.
  • the pharmaceutical formulation may be taken a form which is hardly affected by other drugs even when co-administered with other drugs to be very convenient to take and have more improved therapeutic effect accordingly, and thus it may be a very desirable form.
  • an apixaban pharmaceutical formulation is designed to release the drug from the beginning after the administration of the formulation without the delayed release of a certain period of time as in the prior arts, a change in the drug release pattern due to short-term fluctuation in gastric pH by food and co-administered drug may occur, and furthermore apixaban may be degraded by food and co-administered drug and decreased absorption due to competitive absorption and increased absorption by lipid materials may occur.
  • the present invention may be said to overcome the limitations of the prior arts as described above.
  • the 60 % by weight release time after a drug release lag time of apixaban is within 35 minutes after the release lag time;
  • the 60 % by weight release time after a drug release lag time of apixaban is within 40 minutes after the release lag time;
  • the 60 % by weight release time after a drug release lag time of apixaban is within 60 minutes after the release lag time.
  • the characteristics of the present invention as described above indicate the features of the present invention as immediate-release after initial delayed release and that it is possible to provide a formulation capable of having faster immediate-release when the release lag time is short.
  • the core may comprise at least one selected from the group consisting of 1 to 10 % by weight of an apixaban and a pharmaceutically acceptable salt thereof, with 90 to 99 % by weight of a pharmaceutically acceptable carrier, based on the total weight of the core.
  • the pharmaceutically acceptable carrier may include fillers, binders, disintegrators, surfactants, lubricants, and the like.
  • the filler includes starch, lactose, anhydrous lactose, microcrystalline cellulose, silicified microcrystalline cellulose, silicic anhydride, calcium phosphate, calcium phosphate anhydrous, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, calcium silicate, dextrin, dextrose, dextrates, mannitol, maltose, sorbitol, sucrose, and the like, and these may be used alone or in combination of two or more.
  • the binding agent includes povidone, copovidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, guar gum, xanthan gum, and the like, and these may be used alone or in combination of two or more.
  • the disintegrator includes crospovidone, croscarmellose sodium, sodium starch glycolate, pregelatinized starch, low-substituted hydroxypropyl cellulose, grain starch, and the like, and these may be used alone or in combination of two or more.
  • the surfactant is generally used to help wet the hydrophobic drug and include, for example, sodium lauryl sulfate, sodium stearate, polysorbate 80, poloxamer, and the like, and these may be used alone or in combination of two or more.
  • the lubricant includes magnesium stearate, stearic acid, talc, silicon dioxide, sodium stearyl fumarate, sodium lauryl sulfate, poloxamer, and the like, and these may be used alone or in combination of two or more.
  • the pharmaceutical formulation of the present invention may comprise a disintegrator, as the pharmaceutically acceptable carrier, from 1 to 40 % by weight, preferably from 2 to 20 % by weight, more preferably from 5 to 10 % by weight, based on the total weight of the core.
  • a disintegrator as the pharmaceutically acceptable carrier, from 1 to 40 % by weight, preferably from 2 to 20 % by weight, more preferably from 5 to 10 % by weight, based on the total weight of the core.
  • the disintegrator is included in the above-mentioned range, it is preferable since immediate-release of apixaban can be effectively performed at the time of immediate-release after initial delayed release.
  • the pharmaceutical formulation of the present invention may comprise one or more filler selected from the group consisting of microcrystalline cellulose, anhydrous lactose, and silicified microcrystalline cellulose, as the pharmaceutically acceptable carrier, from 10 to 80 % by weight, preferably from 30 to 60 % by weight, more preferably from 40 to 50 % by weight, based on the total weight of the core.
  • the filler is included in the above-mentioned range, it is preferable since immediate-release of apixaban can be effectively performed after initial delayed release.
  • the pharmaceutical formulation of the present invention relates to a pharmaceutical formulation for delayed release of drug, comprising: a core comprising at least one selected from the group consisting of an apixaban and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and a coated layer for the core; and also provides an in vitro drug release rate capable of securing pharmacokinetic parameters similar to those of a commercially available formulation (Eliquis Tab.®), while effectively inhibiting the increase in moisture in the core by the coated layer.
  • a pharmaceutical formulation for delayed release of drug comprising: a core comprising at least one selected from the group consisting of an apixaban and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and a coated layer for the core; and also provides an in vitro drug release rate capable of securing pharmacokinetic parameters similar to those of a commercially available formulation (Eliquis Tab.®), while effectively inhibiting the increase in moisture in the core by the coated layer.
  • the coating material for forming the coated layer at least one selected from the group consisting of hypromellose, hydroxypropylcellulose, hydroxypropylmethylcellulose acetate succinate, polyvinyl alcohol, povidone, ethylcellulose, methylcellulose, methyl methacrylate-ethyl acrylate copolymer, ethyl methacrylate-chlorotrimethyl ammonium ethyl methacrylate copolymer, and the like may be used.
  • the coated layer may comprise the coating material in an amount of 1 to 30 parts by weight, preferably 2 to 15 parts by weight, more preferably 2 to 10 parts by weight, based on 100 parts by weight of the core.
  • the weight ratio of the coated layer is too small, moisture permeation becomes easy, and thus there is a problem that moisture increment becomes large. If the weight ratio of the coated layer is too large, it is effective to prevent moisture permeation, but it may slow the drug release lag time and drug release rate to adversely affect bioavailability.
  • the amount of the coating material is more than 30% by weight, the release of the drug become too delayed or the release rate of the drug become too lower, and thus the drug is released after about 6 hours, which is the transit time to the small intestine of a human, to be undesirable in terms of absorption of the drug.
  • At least one selected from the group consisting of ethyl cellulose and methyl methacrylate-ethyl acrylate copolymer is preferably used in consideration of the digestion environment of the formulation.
  • the ethyl cellulose may be used in admixture with at least one selected from hypromellose and polyvinyl alcohol in order to control the release delay performance.
  • the ethyl cellulose and at least one selected from hypromellose and polyvinyl alcohol are mixed in a weight ratio of 1.5 to 50:1 in order to easily satisfy the requirement according to the digestion environment of the formulation.
  • the coating materials make it easy to prepare the formulation such that the drug release lag time is 5 to 360 minutes and the apixaban dissolves 60 % or more by weight within 60 minutes after the lag time.
  • the coating materials may be preferably used to achieve delayed release and immediate-release after the release lag time as described above.
  • the 60 % by weight release time after a drug release lag time of apixaban is within 60 minutes after the release lag time;
  • the 60 % by weight release time after a drug release lag time of apixaban is within 60 minutes after the release lag time.
  • the pharmaceutical formulation of the present invention can appropriately control the release time of 60% by weight after the drug release lag time within 60 minutes despite the increase or decrease of the used amount of the coating material.
  • the coating composition for forming the coated layer may further comprise conventional fillers such as plasticizers (polyethylene glycol, triacetin, lactose, and the like), and pigments (titanium oxide, iron oxide, titanium, and the like) together with the coating material.
  • plasticizers polyethylene glycol, triacetin, lactose, and the like
  • pigments titanium oxide, iron oxide, titanium, and the like
  • the coating composition for forming the coated layer may comprise 40 to 100% by weight of the coating material and 0 to 60% by weight of the filler, based on the total weight of the composition. Wherein, 0 % by weight represents the case where no filler is comprised.
  • a secondary coating may be provided for aesthetic purposes or to facilitate identification of the tablet.
  • the dissolution rate of apixaban may be the result of performing the dissolution test in vitro in accordance with the following dissolution standards.
  • the dissolution test may be carried out at 900 mL of dissolution medium at 37°C using a USP Apparatus 2 (paddle) method at a rotation speed of 75 rpm. After a period of time from the start of the test, the sample is removed and analyzed for apixaban at 280 nm by HPLC. 0.05 M sodium phosphate at a pH 6.8 with 0.05% by weight SLS solution as the dissolution medium may be used.
  • the dissolution test may be carried out with reference to the method disclosed in Korean Patent No. 10-1796300.
  • the apixaban pharmaceutical formulations of the present invention may be used for the treatment or prevention of thromboembolic disorders.
  • the thrombotic disorders include deep vein thrombosis, acute coronary syndrome, apoplexy, pulmonary embolism, and the like.
  • the amount of apixaban included in the pharmaceutical formulation of the present invention may be generally from 2.5 to 5 mg, and the apixaban may be usually administered orally twice a day, but may be used for treatment in amounts outside of the range and other administration frequency depending on the condition of the patient and the like.
  • the present invention relates to
  • step (b) compressing the mixture from step (a) by a direct compression method to produce a core tablet, or dry-granulating and compressing the mixture from step (a) to produce a core tablet;
  • the pharmaceutical formulation of the present invention is characterized in that it is prepared without using moisture except for the film coating process in order to suppress the hydrolysis of apixaban by moisture exposure during the manufacturing process.
  • a wet granulation method is a manufacturing method in which granulation is carried out after combining raw materials using a solvent and drying them at a high temperature, and a solvent is essentially introduced into the manufacturing process. If purified water is used as a solvent at this time, apixaban may be hydrolyzed and degradation of apixavan may be promoted by heat at high temperature drying.
  • the pharmaceutical formulation of the present invention is characterized in that it is prepared using a dry granulation method or a direct compression method in which a solvent is not used to suppress degradation of apixaban caused by moisture and heat and no drying process is performed.
  • the coating tablets of example 1 to 10 and comparative examples 1 and 2 were prepared by sequentially performing the granulation by the dry granulation method, the preparation of the tablet, and the coating process through the steps of:
  • the coating tablets of examples 11 to 15 were prepared by sequentially performing the preparation of the core tablet by the powder compression method and the coating process through the steps of:
  • the pharmaceutical formulations of comparative examples 3 and 4 were prepared by the following method.
  • the coating tablets of comparative examples 3 and 4 were prepared by sequentially performing the granulation by the wet granulation method, the preparation of the tablet, and the coating process through the steps of:
  • Test Example 1 in vivo dissolution test
  • the dissolution test was carried out in 900 mL of solvent medium at 37°C using a USP apparatus 2 (paddle) method at a rotation speed of 75 rpm in the same manner as in the method disclosed in the Korean Patent No. 10-1796300.
  • Samples were taken at 5, 10, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 420, 480 minutes after the start of the test, and were analyzed for apixaban at 280 nm by HPLC.
  • a medium for the dissolution test 0.05 M sodium phosphate at a pH 6.8 containing a 0.05 % by weight of sodium lauryl sulphate (SLS) solution was used.
  • SLS sodium lauryl sulphate
  • Drug lag time None None None More than 10 minutes More than 15 minutes More than 150 minutes More than 270 minutes _ 60% by weight release timeafter drug lag time _ _ _ Within20 minutes Within 30 minutes Within 60 minutes Within 60 minutes _
  • Example 6 Example 7
  • Example 8 Example 9
  • Example 10 5 9.4 0 0 0 0 10 50.6 7.8 0 9.9 0 15 76.7 61.1 42.2 58.1 0 30 88.8 83.6 66.3 85.6 0 45 91.0 81.0 95.9 0 60 92.1 85.4 96.1 26.6 90 89.5 98.6 72.4 120 89.9 180 90.2 210 93.5 Content of coating material to core tablet 2 wt. % 5 wt. % 10 wt. % 2 wt. % 10 wt. % Druglag time More than 5 minutes More than 10 minutes More than 10 minutes More than 10 minutes More than 45 minutes 60% by weight release timeafter drug lag time Within 10 minutes Within 20 minutes Within 35 minutes Within 20 minutes Within 45 minutes
  • the initial delayed release of the drugs did not occur in comparative examples 1 and 2 even when the content of the coating material was increased, but as the content of the coating material was increased, the release lag time (the time from zero to the last time point in minute at which the dissolution rate of apixaban is detected to be less than 10 % by weight) was increased in the examples and the fast release of more than 60% by weight within 60 minutes after the drug release lag time was shown.
  • the hygroscopicity was measured by putting the specimens prepared according to the examples and the comparative examples above in the stability test chamber and observing the change amount of the tablet weight under high temperature and high humidity conditions (40°C, 75 % relative humidity).
  • Test Example 4 In vivo test
  • Eliquis Tab.® 5 mg a commercially available formulation of apixaban, and the formulation of example 2 were crossover to 8 beagle dogs, which were divided into two groups, and then the pharmacokinetic parameters AUC, Cmax was calculated by measuring the concentration of apixaban in the blood and the results are shown in Table 8 below.

Abstract

La présente invention concerne une formulation pharmaceutique d'apixaban pour la libération retardée du médicament, comprenant : un noyau contenant au moins un élément choisi dans le groupe constitué d'un apixaban et d'un sel de qualité pharmaceutique de celui-ci, et un support de qualité pharmaceutique ; et une couche de revêtement pour le noyau, caractérisée en ce que le temps de latence jusqu'à la libération du médicament varie de 5 à 360 minutes et 60 % ou plus en poids de l'apixaban se dissolvent en 60 minutes à l'issue du temps de latence jusqu'à la libération du médicament, le temps de latence jusqu'à la libération du médicament étant défini comme le temps nécessaire pour que le taux de dissolution de l'apixaban détecté soit inférieur à 10 % en poids, comme mesuré dans 900 mL d'un milieu de dissolution à 37 °C à l'aide d'un appareil USP2 avec une vitesse de rotation de 75 tr/min ; et son procédé de préparation.
PCT/KR2019/005795 2018-05-14 2019-05-14 Formulation pharmaceutique comprenant de l'apixaban et son procédé de préparation WO2019221488A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0055075 2018-05-14
KR1020180055075A KR20190130411A (ko) 2018-05-14 2018-05-14 아픽사반 약제학적 제제 및 그의 제조방법

Publications (1)

Publication Number Publication Date
WO2019221488A1 true WO2019221488A1 (fr) 2019-11-21

Family

ID=68540479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/005795 WO2019221488A1 (fr) 2018-05-14 2019-05-14 Formulation pharmaceutique comprenant de l'apixaban et son procédé de préparation

Country Status (2)

Country Link
KR (1) KR20190130411A (fr)
WO (1) WO2019221488A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577035A (zh) * 2021-09-07 2021-11-02 山东仁和制药有限公司 一种阿哌沙班片及其制备方法
WO2022115051A1 (fr) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Procédé de compression directe pour formulations d'apixaban non micronisées

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070238674A1 (en) * 2006-04-06 2007-10-11 Veltri Enrico P Tra combination therapies
US20130064888A1 (en) * 2011-08-08 2013-03-14 Roey Solomonovich Pharmaceutical formulations
CN103830199A (zh) * 2014-03-24 2014-06-04 重庆东得医药科技有限公司 含阿哌沙班的药用制剂及其制备方法
US20170202824A1 (en) * 2010-02-25 2017-07-20 Bristol-Myers Squibb Company Apixaban formulations
WO2017182908A1 (fr) * 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Compositions pharmaceutiques d'apixaban

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662542A1 (fr) 2006-09-12 2008-03-20 Glaxo Group Limited Composition pharmaceutique comprenant une pluralite de mini-comprimes contenant un inhibiteur du facteur xa
RU2012101214A (ru) 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
MX2013006877A (es) 2010-12-15 2013-07-05 Merrion Res Iii Ltd Composiciones farmaceuticas para inhibidores selectivos del factor xa para administracion oral.
CA2934120A1 (fr) 2013-12-23 2015-07-02 Laboratorios Del Dr. Esteve, S.A. Composition pharmaceutique orale

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070238674A1 (en) * 2006-04-06 2007-10-11 Veltri Enrico P Tra combination therapies
US20170202824A1 (en) * 2010-02-25 2017-07-20 Bristol-Myers Squibb Company Apixaban formulations
US20130064888A1 (en) * 2011-08-08 2013-03-14 Roey Solomonovich Pharmaceutical formulations
CN103830199A (zh) * 2014-03-24 2014-06-04 重庆东得医药科技有限公司 含阿哌沙班的药用制剂及其制备方法
WO2017182908A1 (fr) * 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Compositions pharmaceutiques d'apixaban

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022115051A1 (fr) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Procédé de compression directe pour formulations d'apixaban non micronisées
CN113577035A (zh) * 2021-09-07 2021-11-02 山东仁和制药有限公司 一种阿哌沙班片及其制备方法

Also Published As

Publication number Publication date
KR20190130411A (ko) 2019-11-22

Similar Documents

Publication Publication Date Title
WO2015102400A1 (fr) Préparation composite pour une administration orale comportant de l'ézétimibe et de la rosuvastatine
WO2018070671A1 (fr) Composition de comprimé oral de lénalidomide
WO2016114521A1 (fr) Composition de dutastéride sous forme de comprimé présentant une stabilité améliorée
WO2019221488A1 (fr) Formulation pharmaceutique comprenant de l'apixaban et son procédé de préparation
WO2018111002A1 (fr) Comprimé à désintégration orale comprenant un composé de carbamate
WO2020242132A1 (fr) Comprimé gastrorésistant contenant du fumarate de diméthyle
EP3188720A1 (fr) Film dispersible oral de tadalafil et son procédé de préparation
WO2017146286A1 (fr) Composition pharmaceutique à base d'extrait de feuille de ginkgo biloba utilisant une matrice de polymère hydrophile pour libération prolongée, et préparation à libération prolongée utilisant cette dernière
WO2016003194A1 (fr) Phosphate de ténofovir disoproxil, et composition pharmaceutique de celui-ci comprenant un délitant de sel non métallique et un lubrifiant de sel non-métallique
WO2020130502A1 (fr) Composition pharmaceutique comprenant l'empagliflozine et la sitagliptine
WO2017073897A1 (fr) Composition pharmaceutique comprenant de la metformine et de la lobéglitazone
WO2023068839A1 (fr) Comprimé enrobé de film présentant une stabilité améliorée contenant du montélukast ou son sel pharmaceutiquement acceptable et de la lévocétirizine ou son sel pharmaceutiquement acceptable
WO2018160011A1 (fr) Composition pharmaceutique présentant des caractéristiques améliorées de formation de comprimés selon le contrôle de taille des particules de pirfénidone, et son procédé de préparation
WO2021167364A1 (fr) Composition pharmaceutique comprenant de l'ésoméprazole et du bicarbonate de sodium présentant d'excellentes propriétés de libération
WO2021145676A1 (fr) Comprimé comprenant de l'atorvastatine et de l'ézétimibe
WO2021125824A1 (fr) Formulation pharmaceutique comprenant de la cibenzoline ou un sel de celle-ci
WO2021002588A1 (fr) Composition pharmaceutique contenant de la tamsulosine ou un chlorhydrate de tamsulosine et procédé de préparation associé
WO2016122256A1 (fr) Composition pharmaceutique comprenant du candésartan et de l'amlodipine
WO2018044020A1 (fr) Procédé de préparation de microsphère à libération prolongée d'épérisone, et préparation composite de microsphère à libération prolongée d'épérisone et d'acéclofénac
WO2013169082A1 (fr) Préparation orale à libération contrôlée de bosentan
WO2016153222A2 (fr) Composition pharmaceutique comprenant un sel de potassium de telmisartan et procédé de préparation associé
WO2019245150A1 (fr) Composition pharmaceutique comprenant du cilostazol et un médicament à base de statine
WO2013187700A1 (fr) Formulation pharmaceutique combinée comprenant de la métformine et un inhibiteur de la hmg-coa réductase
WO2021215856A1 (fr) Préparation à enrobage entérique comprenant de la pirfénidone ayant une sécurité et une stabilité améliorées, et son procédé de préparation
WO2018062941A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une démence et d'un dysfonctionnement cognitif, contenant du donépézil ou un sel de qualité pharmaceutique de celui-ci et de la mémantine ou un sel de qualité pharmaceutique de celle-ci, et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19804014

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19804014

Country of ref document: EP

Kind code of ref document: A1